^
Association details:
| Biomarker: | BRCA2 deletion + ATM mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer
Published date:
09/23/2020
Excerpt:
Notably, study subject 16 (BRCA2 loss and ATM frameshift mutation) showed outstanding response to consecutively carboplatin, PARPi and carboplatin rechallenge, with maximum PSA decline of 99%, 83% and 82%, respectively.
DOI:
10.1002/ijc.33306
